Vivani Medical reported Q3 2026 financial results and expects to announce top-line data from its SLIM-1 Phase 1 trial of NPM-139, a long-acting semaglutide implant for chronic weight management, later this week. The implant aims to improve medication adherence by allowing dosing once or twice a year, with a unique reversible feature. Vivani also updated on the pending Cortigent-ClearOne merger and plans for a Phase 2 study in 2027. The company ended Q3 with $15.5 million in cash and a net loss of $7.3 million for the quarter.
Vivani Medical's Q3 2026 financial results and business update provide context for readers. For those following the health sector, here is Pluang's market snapshot as of Nov 12, 2026 04:11 WIB: Among 150 priced health-sector US stocks, 87 rose and 61 fell. Summit Therapeutics Inc (SMMT) traded at USD 16.71 with a 6.28% decline and a typical hold time of 19 days, while Twist Bioscience Corp (TWST) was priced at USD 124.10, down 6.08% but with 100% buy order activity and a longer hold time of 27 days. Revolution Medicines Inc (RVMD) stood at USD 181.41, down 6.03%, with a shorter hold time of 13 days.
AeroVironment secured a $405 million international order for its LOCUST X3 high-energy laser weapon systems, enhancing counter-drone defense capabilities in the Middle East amid rising regional security threats. Following the announcement, AeroVironm...
Vestas Wind Systems reported Q3 2026 earnings per share of $0.13 and revenue of $6.34 billion, both below analyst expectations. The company's profit was impacted by weak sales volume and a broken turbine blade. Following the earnings miss, Vestas' sh...
The global beverage market is projected to grow from $2.03 trillion in 2026 to $2.78 trillion by 2032, at a CAGR of 5.35%. Growth is fueled by rising demand for nonalcoholic and functional beverages, convenience packaging, and premium products for sp...
DelveInsight's 2026 report reveals more than 200 GLP-1 receptor agonists and incretin-based therapies are in development by over 180 companies, targeting conditions like type 2 diabetes, obesity, and related metabolic disorders. Key players such as E...
Tennessee American Water has applied an additional $13.07 credit to customer accounts, bringing total PFAS settlement refunds to over $84 per customer. This credit follows approval from the Tennessee Public Utility Commission, allowing the company to...
